Pharmaceutical Preparations · CAMBRIDGE, MA, United States
$26.77
-0.06% (-$0.02)2026-08-06
Smart-Money SignalNeutral · 54/100— Insiders are net buyers over 90 days ($26.5M, 9 buys vs 8 sales)
Price Performance
Historical data including institutional events
Company Profile
K
Kevin Lind
CEO & Executive Director
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
